Launched in July 2020, Project ACTT is a Canadian program providing circulating tumor DNA (ctDNA) testing as an alternative to surgical tissue biopsy for patients with metastatic or recurrent lung cancer. COVID-19 made it clear ctDNA testing should be considered a first-line alternative when tissue biopsies are not available.
The Canadian Digital Technology Supercluster invested in this consortium initiative led by Canexia Health to deploy and enhance its minimally-invasive ctDNA test during the pandemic. Partners include AstraZeneca Canada, Queen’s University, LifeLabs, Illumina, Eastern Ontario Regional Laboratory, and Genolife.
Read The Full Press Release